AL-37350A
AL-37350A, also known as 4,5-dihydropyrano-α-methyltryptamine, is a serotonin receptor agonist and tricyclic tryptamine derivative related to the psychedelic tryptamine 5-MeO-AMT. It acts as a potent and selective agonist for the serotonin receptor 5-HT2A, with a Ki of 2.0nM, and moderate selectivity over the related 5-HT2B and 5-HT2C receptors. The drug has been shown to have ocular hypotensive activity in animal models, suggesting it may be useful for the treatment of glaucoma. AL-37350A was first described in the scientific literature by Jesse May and colleagues in 2003.